Company intelligence / Profile preview
Oxcia
Stockholm, Swedenoxcia.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
OXC-101 has demonstrated promising efficacy and safety profiles in early clinical trials for hard-to-treat cancers, including AML and pancreatic cancer. It has received FDA Orphan Drug Designation for AML. OXC-201 shows promise in preclinical models of IPF and other fibrotic/inflammatory diseases.
- Therapeutic areas
- OncologyDermatologyPulmonologyRare Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
LEO Pharma (dermatology research collaboration)SciLifeLab Drug Discovery and Development Platform (academic/industry collaboration)
Beyond the preview
Go deeper on Oxcia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oxcia.